SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Concordium is the Layer-1 blockchain built for a new era of digital trust. With mandatory, privacy-preserving identity verification built into its consensus layer, utilizing zero-knowledge proof technology. Concordium also enables Protocol-level tokens that eliminate smart contract risks by being issued directly at the consensus layer, with built-in features that provide the infrastructure for compliance-ready use cases. At its core is Smart Money - programmable, identity-embedded, and compliance-ready value that powers trusted interactions across Web3. Smart Money enables frictionless exchange, automation, and verifiable trust by design. Unlike conventional blockchains, Concordium integrates trust, accountability, and privacy into its architecture from the ground up  bridging traditional systems and Web3 to build a transparent, sustainable digital future. The name Concordium comes from the Latin concordia—meaning harmony and agreement—a reflection of its mission to build infrastructure that embeds trust, privacy, and compliance into every interaction.

Concordium

Concordium ($CCD) is trending as community members highlight its focus on privacy, compliance, and real-world utility, positioning it as a key infrastructure play for stablecoins and PayFi. Recent partnerships, including integration with bitcoin.com wallets, are also sparking increased interest and bullish sentiment. The community believes its unique approach to verifiable trust and on-chain identity is setting it up for significant growth.

monday.com Ltd. engages in the business of operating a cloud-based visual work operating system that consists of modular building blocks that can be easily used and assembled to create software applications and work management tools and serves as a connective layer to integrate with various digital tools across an organization. It operates through the following geographical segments: United States, EMEA, United Kingdom, and Rest of the World. The company was founded by Roy Mann, Eran Kampf, and Eran Zinman in 2012 and is headquartered in Tel Aviv, Israel.

Monday.Com Ltd

Monday.com Ltd

Monday.com is trending due to a significant sell-off following earnings, despite the company beating expectations; the community is actively debating whether this drop is an overreaction or a sign of deeper issues. Community members are also discussing the impact of AI on the company's future, as well as a recent analyst downgrade. Despite the negative sentiment, some investors view the dip as a buying opportunity, citing the company's strong fundamentals and growth potential.

Avalanche is a high throughput smart contract blockchain platform. Validators secure the network through a proof-of-stake consensus protocol. It is said to be fast, low cost, and environmental friendly.

Avalanche

Avalanche is trending amid discussions about its potential for growth and recent partnerships, with community members pointing to a Nasdaq-listed company's planned investment in AVAX tokens as a catalyst. The community is actively debating entry points and speculating on short-term price movements. Some traders anticipate a broader altcoin season could further boost AVAX.

Litecoin is a peer-to-peer cryptocurrency created by Charlie Lee. It was created based on the Bitcoin protocol but differs in terms of the hashing algorithm used. Litecoin uses the memory intensive Scrypt proof of work mining algorithm. Scrypt allows consumer-grade hardware such as GPU to mine those coins.  Why Litecoin? Litecoin is a cryptocurrency that has evolved from Bitcoin after its own popularity in the industry, this alternative, or ‘altcoin’ has emerged to allow investors to diversify their digital currency package, according to Investopedia. Litecoin is one of the most prominent altcoins and was created by former Google employee and Director of Engineering at Coinbase, Charlie Lee. Litecoin was the first to alter Bitcoin and the most significant difference is that it takes 2.5 minutes for Litecoin to generate a block, or transaction, in comparison to Bitcoin's 10 minutes.  ‘While this matters little to traders, miners who use hardware to run Bitcoin's network cannot switch over to Litecoin. This keeps bigger mining conglomerates away from Litecoin because they cannot easily optimize their profits by swapping to another coin, contributing to a more decentralized experience. Litecoin also has bigger blocks, and more coins in circulation, making it more affordable and swift when transacting,’ Investopedia explained.  As explained above, Litecoin can transact a lot faster than Bitcoin, but there are also a number of other characteristics that investors need to know before trading. Litecoin can handle higher volumes of transactions because of the capability of transacting faster and if Bitcoin attempted to transact on the scale of its altcoin, a code update would be needed. However, Litecoin’s blocks would be larger, but with more ‘orphaned blocks'. The faster block time of litecoin reduces the risk of double spending attacks - this is theoretical in the case of both networks having the same hashing power.  Litecoin Technical Details: The transaction confirmation time taken for Litecoin is about 2.5 minutes on average (as compared to Bitcoin's 10 minutes). The Litecoin network is scheduled to cap at 84 million currency units.   Litecoin has inspired many other popular alternative currencies (eg. Dogecoin) because of its Scrypt hashing algorithm in order to prevent ASIC miners from mining those coins. However it is said that by the end of this year, Scrypt ASIC will enter the mass market.

Litecoin

Litecoin is trending as the community speculates on potential breakouts and considers it an undervalued cryptocurrency. Some view LTC as a strong buy under $100, citing its long-term adoption and recent privacy upgrades. Discussions also revolve around its relationship with Bitcoin's price movements and whether it signals a broader altcoin season.

$SWEAT is the beating heart of the Movement Economy—a groundbreaking token that transforms physical activity into real-world value. Minted through movement, $SWEAT rewards your steps with a crypto asset that you can earn, trade, or grow. The team states that their app has increased their users’ physical activity by an average of 20%, creating a healthier society and reducing burdens on global healthcare systems. With over 20 million holders, SWEAT is eliminating barriers and making Web3 accessible to everyone, one step at a time.

Sweat Economy

$SWEAT is trending as the community anticipates its potential, with many expressing long-term bullish sentiment. Discussions revolve around staking, accumulating coins through the Sweatcoin app by walking, and hopes for a future bull run. Some users are highlighting its unique incentive for healthy activity, while others await broader availability and speculate on future price movements.

Internet Computer (IC) is the world’s first blockchain that is capable of running at web speed at unrestrictive capacities. Built by the DFINITY Foundation, IC aims to recreate the web by supporting smart contract development at scale and changing the way people can interact using web services. Internet Computer aims to extend the public internet, so that it can be the world’s computing platform, in a decentralized manner. Internet Computer sets to revolutionalize the design of the crypto economy, with an aim to overhaul traditional software services.   The project was founded in October 2016 by Dominic WIllams and have raised a total of $121 million from investors such as Adreessen Horowitz, Polychain Capital, Multicoin Capital and such. On May 10, 2021, DFINITY launched the Internet Computer into the public domain, marking it a major milestone for ICP as it means the internet now functions as a decentralised global computer. This is marked by the release of all of the Internet Computer’s source code into the public domain, as well as ICP utility token that allows tens of thousands of community members to govern the Internet Computer network.  ICP is Internet Computer's native token. It plays three prominent roles:  1. Network Governance: Users that participate in the governance will be rewarded with ICPI 2. Production of Cycles for Compute: ICP can be converted into cycles where it is used as the transaction fee to access the network. Cycles are burned after used. 3. Rewarding Users: ICP is used as the rewards to incentivize users to participate in the network such as securing the network.

Internet Computer

Internet Computer (ICP) is trending as community members discuss its recent price surge and potential for further growth, fueled by news around CaffeineAI and Motoko upgrades. Bullish investors believe ICP is undervalued and represents the future of a decentralized internet, while others caution about pullbacks and compare it to previous pump-and-dump cycles. Community members are actively discussing buying the dip and anticipating a continued run, potentially driven by AI and cloud-related narratives.

GigaCloud Technology, Inc. specializes in global end-to-end business-to-business (B2B) electronic commerce (e-commerce) for large parcel merchandise. Its B2B ecommerce platform, the “GigaCloud Marketplace” integrates everything from discovery, payments and logistics tools into one easy-to-use platform. The firm offers a comprehensive solution that transports products from the manufacturers warehouse to the end customers doorstep, all in one place. The company was founded by Lei Wu on August 29, 2006 and is headquartered in El Monte, CA.

GigaCloud Technology Inc - Ordinary Shares - Class A

GigaCloud Technology Inc

GigaCloud Technology ($GCT) is trending as investors discuss its low P/E ratio and growth potential despite mixed sentiment around tariffs and potential insider selling; the community awaits the upcoming earnings report with anticipation of a strong showing that could catalyze a price surge. A recent settlement regarding claims of misleading investors is also circulating, though some believe GCT's unique logistics model and expansion into Europe position it for long-term success.

Definitive is an onchain trading platform democratizing advanced trading tools for the masses. Trade any token on any chain with advanced trade order types including Market, Limit Buy/Sell, Stop Loss and TWAP orders.  Route your trade instantly across 100+ DEXs and liquidity pools to get the best prices on every trade. Definitive is built by former Coinbase Institutional trading alumni and active DeFi experts.

Definitive

EDGE crypto is trending as the community buzzes about a new listing and upcoming portal launch with updates. Token buybacks are underway, fueling speculation of significant moves, while some compare its potential to previous runners and highlight its low market cap on Coinbase. Community members are closely watching for a breakout, citing increased volume and bullish chart patterns.

Veeva Systems, Inc. engages in the provision of industry cloud solutions for the global life sciences industry. Its solutions enable pharmaceutical and other life sciences companies to realize the benefits of modern cloud-based architectures and mobile applications for their most critical business functions, without compromising industry-specific functionality or regulatory compliance. The firm's customer relationship management solutions enable its customers to increase the productivity and compliance of their sales and marketing functions. Its regulated content management and collaboration solutions enable its customers to more efficiently manage regulated, content-centric processes across the enterprise. The company's customer master solution enables customers to more effectively manage complex healthcare provider and healthcare organization data. The company was founded by Mark Armenante, Peter P. Gassner, Doug Ostler, Mitch Wallace and Matthew J. Wallach on January 12, 2007, and is headquartered in Pleasanton, CA.

Veeva Systems Inc - Ordinary Shares - Class A

Veeva Systems (VEEV) is trending due to positive analyst ratings and price target increases after recent earnings, with discussion focusing on its growth prospects and expanding partnerships in the life sciences sector. Community interest is driven by its potential to reach new all-time highs, although rising costs and competition remain a concern. The stock's breakout potential and integration of AI are key talking points.

Confluent, Inc. engages in creating a data infrastructure platform focused on data in motion. The firm provides application architecture engagement, multi data center, security and upgrade engagement, and Amazon web services cloud deployment services. Its products include Confluent Cloud, Confluent Platform, WarpStream BYOC, Connectors, Flink, Stream Governance, and Confluent Hub. The company was founded by Edward Jay Kreps, Neha Narkhede, and Jun Rao on September 1, 2014, and is headquartered in Mountain View, CA.

Confluent Inc - Ordinary Shares Class A

Confluent Inc

Confluent (CFLT) is trending amid speculation of a potential sale, driving significant conversation in investment communities. Fueled by reports of takeover interest from private equity and tech firms, traders are weighing the possibility of a bidding war and projecting potential buyout prices. The community is also analyzing Confluent's advancements in streaming data and AI, and how those technologies might attract further acquisition interest.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

4D Molecular Therapeutics (NASDAQ:FDMT) Raised to Equal Weight at Morgan Stanley

Morgan Stanley upgraded shares of 4D Molecular Therapeutics from an "underweight" rating to an "equal weight" rating in a report on Friday...

<ul class="summary-bullets"><li>4D-150 demonstrated consistent and durable benefits in patients with wet age-related macular degeneration in the study.&nbsp;</li><li>The company is currently enrolling patients into late-stage trials for the drug.</li><li>Enrollment is continuing ahead of initial projections, CEO David Kirn said. &nbsp;</li></ul>4D Molecular Therapeutics (FDMT) announced on Thursday that its experimental drug 4D-150 demonstrated consistent and durable benefits in patients with wet age-related macular degeneration in an early-to-mid-stage trial.Wet age-related macular degeneration (AMD) is an advanced form of macular degeneration where abnormal blood vessels grow in the retina, leak fluid or blood, and cause a rapid decline in central vision. The proliferation and leakage of abnormal blood vessels is stimulated by vascular endothelial growth factor (VEGF), a protein that promotes the growth of new blood vessels. According to 4D, the disease has a high incidence, with 200,000 individuals estimated to be newly diagnosed every year in the U.S. alone.<h2 class="st-heading-2">Study Findings</h2>4D-150 showed maintenance of visual acuity and control of retinal anatomy in the study, the company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.4dmoleculartherapeutics.com/news-releases/news-release-details/4dmt-announces-positive-long-term-data-phase-12-prism-clinical">said</a>. The study also reduced treatment burden as patients maintained a consistent and clinically meaningful reduction in supplemental injections in 6-month intervals following dosing with 4D-150 through up to two years of follow-up, it added.4D-150 was further well tolerated with no new safety or intraocular inflammation findings. The drug is aimed at providing multi-year, and potentially lifelong, sustained delivery of anti-VEGF from the retina with a single, safe, intravitreal injection. Anti-VEGF is a treatment that blocks the action of the vascular endothelial growth factor.The company is currently enrolling patients into late-stage trials for the drug. Enrollment is continuing ahead of initial projections, according to CEO David Kirn.“With the robust PRISM dataset and our APAC region strategic partnership with Otsuka announced last week, we are well positioned for global success in our Phase 3 4FRONT clinical trials, which continue to enroll ahead of initial projections,” he added. &nbsp;<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Shares of the company soared 13% in the pre-market session at the time of writing. On Stocktwits, retail sentiment regarding <a href="https://stocktwits.com/symbol/FDMT">FDMT stock</a> remained within the ‘bullish’ territory, while message volume remained at ‘high’ levels over the past 24 hours.FDMT stock is up 89% this year and approximately 26% over the past 12 months.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/dupont-announces-2-billion-share-buyback-stock-tumble-7-today/cL2t8hLREbz">DuPont Announces $2 Billion Share Buyback: Why Did The Stock Tumble 7% Today?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

Global stock market chart and trading board - stock photo

FDMT Stock Gains Pre-Market After Positive Study Data For Experimental Drug In Eye Disease

The drug showed maintenance of visual acuity, control of retinal anatomy, and reduction of treatment burden at all time points with up to 2 years of follow-up. 

Equity

The drug showed maintenance of visual acuity, control of retinal anatomy, and reduction of treatment burden at all time points with up to 2 years of follow-up. 


Wall Street Analysts See a 208.52% Upside in 4D Molecular Therapeutics (FDMT): Can the Stock Really Move This High?

The average of price targets set by Wall Street analysts indicates a potential upside of 208.5% in 4D Molecular Therapeutics (FDMT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

SNY's Gene Therapy Candidate for Eye Disease Gets FDA Fast Track Tag

Sanofi's gene therapy SAR402663 for wet AMD earns FDA fast track status, aiming to speed up development and reduce treatment burden.

4D Molecular Therapeutics, Inc. (FDMT) Reports Q2 Loss, Misses Revenue Estimates

4D Molecular Therapeutics (FDMT) delivered earnings and revenue surprises of -11.36% and -98.58%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of 4D Molecular Therapeutics, Inc. - FDMT

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of 4D Molecular Therapeutics, Inc. - FDMT INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors...

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of 4D Molecular Therapeutics, Inc. - FDMT

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of 4D Molecular Therapeutics, Inc. - FDMT SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of...

Kaskela Law LLC Announces Stockholder Investigation of 4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) and Encourages Investors to Contact the Firm

Kaskela Law LLC announces that it is investigating 4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) (4D Molecular) on behalf of the companys stockholders. Since March 2024, shares of 4D Moleculars...

FDMT Investors Have Opportunity to Join 4D Molecular Therapeutics, Inc. Securities Fraud Investigation with the Schall Law Firm

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of 4D Molecular Therapeutics, Inc. (4D Molecular Therapeutics or...

4DMT operates as a clinical-stage genetic medicines company focused on inventing and developing genetic medicines to treat large market diseases in ophthalmology, pulmonology and cardiology. It develops genetic medicines using its proprietary invention platform, Therapeutic Vector Evolution. It combines the power of the Nobel Prize-winning technology, directed evolution, with approximately one billion synthetic AAV capsid-derived sequences. Its product design, development and manufacturing engine create a valuable and diverse product pipeline. The company is currently advancing five clinical-stage and two preclinical product candidates, each tailored to address rare and large market diseases. 4DMT was founded by David H. Kirn, Melissa Kotterman, Theresa Janke, and David Schaffer on September 12, 2013 and is headquartered in Emeryville, CA.

4D Molecular Therapeutics Inc

$ASTS

$RKLB

$BBAI

$NBIS

Which earnings release are you most excited for the week of Nov. 10? 
 
Drop a comment for others.

FDMT
4D Molecular Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest FDMT News

FDMT4D Molecular Therapeutics Inc